Arphio's Outlook in Orphan Drug Distribution for 2024

18.01.2024

In a strategic move to enhance our global footprint in orphan drug distribution, Arphio would like to share its ambitious outlook for 2024. 

Emphasising our commitment to making a significant impact on the global market for orphan drugs, Arphio is fuelled to transform the lives of individuals dealing with rare diseases.

This year, Arphio directs its strategic focus towards the European Union (EU), Asia-Pacific (APAC), Gulf Cooperation Council/Middle East and North Africa (GCC/MENA), Latin America (LATAM), and Russia/Commonwealth of Independent States (RU/CIS) regions. The primary objective is to address gaps in access to critical treatments and establish partnerships that align with Arphio's core mission. 

Understanding the distinctions of each region is fundamental to Arphio's approach. Tailoring solutions that align with local healthcare needs, ensuring a meaningful and lasting impact. Arphio invites potential collaborators in the pharmaceutical, biotech, and healthcare sectors to explore mutually beneficial opportunities.

Partner up now!

At Arphio, our mission is to make treatments for rare diseases accessible to a wide international population. Get in touch today.

milos.panjkovic@arphio.com - VP, Business Development
tarun.chawla@arphio.com - Director, Business Development
helena.barsky@arphio.com - Senior Business Development Specialist
istvan.tisler@arphio.com - VP, Portfolio & Member of the Board

Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.